Hutchison Medipharma Limited

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Hutchison Medipharma Limited sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 9 completed early-phase tilt top decile by trial count

Hutchison Medipharma Limited: 11 sponsored US clinical trials, none currently recruiting.

Hutchison Medipharma Limited sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 3 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Food-drug Interaction, with 1 trials.

Top-decile sponsor footprint

Hutchison Medipharma Limited ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

9 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

COMPLETED Phase 1

Surufatinib Hepatic Impairment Study

NCT04755075
COMPLETED Phase 1

Surufatinib Renal Impairment Study

NCT04755088
COMPLETED Phase 1

Fruquintinib Food Effect and Proton Pump Inhibitor Study

NCT04645940
COMPLETED Phase 1

Fruquintinib CYP3A Inhibitor and Inducer Study

NCT04557397
COMPLETED Phase 1

A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects

NCT04372394
COMPLETED Phase 3

A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer

NCT04322539
COMPLETED Phase 1

A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects

NCT04372407
COMPLETED Phase 1

Surufatinib DDI With a PPI and a CYP3A Inducer

NCT04510649
COMPLETED Phase 1

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

NCT03251378
TERMINATED Phase 3

HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis

NCT01882764
TERMINATED Phase 3

A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis

NCT01805791

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 3 3

Therapeutic Areas

Food-drug Interaction 1
Drug Interaction 1
Hepatic Impairment 1
Healthy 1

How the Hutchison Medipharma Limited early-phase archive is shaped

11 indexed studies, none listed as recruiting (0% open); 9 completed (82%).

Phase mix: 3 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Food-drug Interaction (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Hutchison Medipharma Limited: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Hutchison Medipharma Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Hutchison Medipharma LimitedAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiome10xBio22nd Century Group23andMe3-C Institute for Social Development
Hutchison Medipharma Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Hutchison Medipharma Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Hutchison Medipharma Limited page

11 registered trials is a research-attention snapshot, not an endorsement of Hutchison Medipharma Limited or any single study.

  • None of Hutchison Medipharma Limited's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Food-drug Interaction is the condition Hutchison Medipharma Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Food-drug Interaction trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Hutchison Medipharma Limited pipeline card: 11 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.